We are a CRO specialising in the analysis of proteins and their associated PTM’s via advanced Mass Spectrometry. By using proprietary methodologies, we can detect up to 8,000 proteins per sample in Discovery mode and can offer multiplexed assays of up to 100 proteins/sample in a GCLP accredited Targeted assay.
With their proprietary bioinformatics software, these can be trimmed down to some tens of proteins that are either up-, or down-regulated with disease progression or drug treatment.
Novogene utilises scientific excellence, a commitment to customer service and unsurpassed data quality to help our clients realise their research goals in the rapidly evolving world of genomics. With over 2,000 employees, multiple locations around the world, 37 NGS related patents, and over 670 publications in top tier journal such as Nature and Science, the company has rapidly become a world-leader in NGS services. In this conference, we will exhibit the latest genome sequencing solutions.
With unwavering commitment, expertise and infrastructure we fuel and strengthen the life science market with our offering of contract manufacturing services for our visionary partners. As a trusted and reliable resource, our goal is to set the standard for partnership excellence in life science.
PerkinElmer, Inc. offers innovative solutions which improve the efficiency of genomic and proteomic workflows while eliminating the challenges associated with them. The HIVE™ scRNAseq solutions for single cell genetic analysis facilitates the remote collection, storage, and shipment of samples for central processing enabling labs to process samples when they want without specialized instrumentation.
Mission Bio is a life sciences company that accelerates discoveries and cures by equipping researchers with the tools they need to improve how we measure and predict our resistance and response to precision therapies. With the Tapestri Platform, the only commercialized platform capable of analyzing DNA and protein simultaneously with single-cell resolution, Mission Bio’s multi-omics approach improves time-to-market for new therapeutics, including innovative cell and gene therapies that provide new pathways to health.